Olafsson Sigurdur O 4

What Happened

• Olafsson Sigurdur O, President & CEO and Director of Keenova Therapeutics plc, received an award of 198,539 restricted stock units (RSUs) on February 25, 2026. The award is reported as a derivative grant (code A) with an acquisition price of $0.00.
• Each RSU will be settled into one ordinary share upon vesting (see footnote). This grant is a compensation award, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-25; Form 4 filed: 2026-02-26 (timely filing).
• Grant: 198,539 RSUs; reported price: $0.00; transaction type: Award (A), derivative.
• Settlement: Each RSU converts to one ordinary share upon vesting (Footnote F1).
• Vesting schedule: RSUs vest ratably on each of the first three anniversaries of February 25, 2027 (Footnote F2).
• Shares owned after transaction: Not disclosed in the Form 4 filing.
• Remarks: The filing also serves as notice to the issuer under Part V of the Companies Act 2014.

Context

• RSUs are a form of equity compensation that convert to shares only when they vest; their eventual value depends on Keenova’s share price at vesting. This grant does not immediately increase Olafsson’s share count until RSUs vest/are settled.